That I didn't know and would like to see a link if possible?
So far the company has identified the WT vs the mutant type of APOE gene as a potential PM.
We have either 0, 1 or 2 APOE3 alleses, but I am not aware of any variants ever mentioned by Anavex.
Having 1 or especially 2 APOE3 alleles lowers the risk of AD. As we saw in sub-Group1 of the P2a AD open label peer reviewed post hoc analysis, those 2 patients that had: APOE3 alleles, were on High Dose, had a baseline MMSE > 20 and the SIGMAR1 WT gene improved their ADCS-ADL score out to 148 weeks.
I doubt that the APOE3 alleles, any variants or not, is a biomarker of response to A2-73. More likely the better performance of those 2 patients was because carries of APOE3 alleles have the lowest AD risk.
AI
